Your browser doesn't support javascript.
loading
Diabetes risk after a normal oral glucose tolerance test during pregnancy.
Dubietyte, Greta; Lauszus, Finn Friis; Guldbech, Arense Vinding; Kaiser, Karsten; Nielsen, Michael Festesen.
Afiliación
  • Dubietyte G; Department of Obstetrics/Gynaecology, Aabenraa Hospital, Sygehus Sønderjylland.
  • Lauszus FF; Department of Obstetrics/Gynaecology, Aabenraa Hospital, Sygehus Sønderjylland.
  • Guldbech AV; Department of Obstetrics/Gynaecology, Aabenraa Hospital, Sygehus Sønderjylland.
  • Kaiser K; Department of Obstetrics/Gynaecology, Aabenraa Hospital, Sygehus Sønderjylland.
  • Nielsen MF; Department of General Surgery, Aabenraa Hospital, Sygehus Sønderjylland.
Dan Med J ; 69(12)2022 11 25.
Article en En | MEDLINE | ID: mdl-36458611
ABSTRACT

INTRODUCTION:

Our aim was to conduct a follow-up of a cohort of women screened for GDM with a normal oral glucose tolerance test (OGTT) during pregnancy to investigate the incidence and time of diagnosis of manifest diabetes mellitus and identify risk factors for subsequent development of diabetes.

METHODS:

This was a follow-up study of a cohort with normal and borderline OGTT in 1991/1992. Among the original 352 women, only five were lost to follow-up.

RESULTS:

In total, 64 women (18%) had manifest diabetes. Their median age was 57 years after 28 years of follow-up. This amounts to three times the expected rate compared with the background population. The rate of manifest diabetes rises 10-20 years after pregnancy and after the age of 40 years. A normal fasting glucose and also a borderline fasting glucose at OGTT during pregnancy were associated with an increased risk of manifest diabetes (p less-than 0.001), also after adjustment for age, Body Mass Index, non-Danish origin and smoking during pregnancy (p less-than 0.002).

CONCLUSION:

The incidence of diabetes is higher in women with various risk factors for DM and a previously normal OGTT in pregnancy than in the background population. Our results are useful in identifying the time during which women may benefit from effective implementation of evidence-based treatment to postpone and avert manifest DM, even though they had a normal OGTT during pregnancy.

FUNDING:

none. TRIAL REGISTRATION The trial was registered with the the Regional Ethics Committee and the Data Protection Agency, nos. 2014-41-3433, 1-16-02-824-17 (under running permission no. 621549), 1-16-02-825-17, and 1-16-02-180-17, all under the cover of data handling agreement no. 509 with the Danish Health Authority.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ayuno / Diabetes Mellitus Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Ethics Límite: Adult / Female / Humans / Middle aged / Pregnancy Idioma: En Revista: Dan Med J Año: 2022 Tipo del documento: Article
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ayuno / Diabetes Mellitus Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Ethics Límite: Adult / Female / Humans / Middle aged / Pregnancy Idioma: En Revista: Dan Med J Año: 2022 Tipo del documento: Article
...